Please assess the completion status of the following clinical trial:

Trial Title: Ofatumumab With Fludarabine and Cyclophosphamide in B-CLL Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with active B-CLL and with an indication for treatment~2. Age ≥ 18 years~3. Following receipt of verbal and written information about the study, the patient must provide signed informed consent before any study related activity is carried out~Exclusion Criteria:~1. Any previous treatment for B-CLL or any other treatments that can be considered active against B-CLL~2. Glucocorticoid unless given in doses ≤ 10 mg /day for other indications than B-CLL (e.g. asthma)~3. Known transformation of B-CLL~4. Known CNS involvement of B-CLL~5. Past or current malignancy, except for:~   1. Cervical carcinoma Stage 1B or less~  2. Non-invasive basal cell and squamous cell skin carcinoma~  3. Malignant melanoma with a complete response of a duration of \> 10 years~  4. Other cancer diagnoses with a complete response of a duration of \> 5 years~6. Chronic or current infectious disease requiring systemic treatment~7. Clinically significant cardiac disease~8. Significant concurrent, uncontrolled medical condition~9. History of significant cerebrovascular disease~10. Known HIV positive~11. Positive serology for hepatitis B, unless due to vaccination~12. Leukapheresis, except as a safety measure before chemotherapy~13. ECOG Performance Status of 3 or 4~14. Patients who at the time of inclusion are not expected to be able to complete the ofatumumab-FC regimen~15. Patients who have received treatment with any non-marketed drug substance or experimental therapy within 4 weeks prior to Visit 1~16. Current participation in any other interventional clinical study~17. Patients known or suspected of not being able to comply with a study protocol (e.g. due to alcoholism, drug dependency or psychological disorder)~18. Breast feeding women or women with a positive pregnancy test at Visit 1~19. Women of childbearing potential not willing to use adequate contraception for up to one year after last dose of ofatumumab. Adequate contraception is defined as hormonal birth control or intrauterine device. For patients in the USA the use of a double barrier method is also considered adequate.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active Comparator 1 (Type: ACTIVE_COMPARATOR): Each patient will receive a total of 6 infusions with ofatumumab every 4 weeks in combination with fludarabine and cyclophosphamide. The first infusion will be 300mg followed by 5 infusions of 500mg
- Active Comparator 2 (Type: ACTIVE_COMPARATOR): Each patient will receive a total of 6 monthly infusions with ofatumumab in combination with fludarabine and cyclophosphamide. The first infusion will be 300mg followed by 5 infusions of 1000mg

Based on this trial design, predict the completion outcome and termination type (if applicable).